Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Lancet Oncol. 2013 Nov;14(12):e562-70. doi: 10.1016/S1470-2045(13)70475-3.
Sarcomas are a rare and diverse set of cancers that disproportionately affect young people. The best possible outcome depends on access to highly specialised, multidisciplinary care. Although advances have been made in therapeutic techniques, access to some treatments might be limited by cost implications. This Review proposes an evidence-based, consensus recommendation for optimum management of bone and soft-tissue sarcoma across the Asia-Pacific region, taking into account variation in health-care resources, stratified according to the Breast Health Global Initiative resource levels. A web-based survey of 89 clinicians involved in the care of patients with sarcoma from 18 Asia-Pacific countries generated the recommendations for diagnosis, staging, and management, including supportive and palliative care, and research.
肉瘤是一组罕见且多样化的癌症,其发病率在年轻人中不成比例。最好的治疗效果取决于能否获得高度专业化的多学科治疗。尽管在治疗技术方面已经取得了进展,但由于成本影响,一些治疗方法的获得可能会受到限制。本综述针对亚太地区的骨和软组织肉瘤提出了一种基于循证的共识推荐意见,该推荐意见考虑到了医疗资源的差异,并根据 Breast Health Global Initiative 资源水平进行了分层。通过对来自 18 个亚太国家的肉瘤患者治疗相关的 89 名临床医生进行在线调查,提出了诊断、分期和治疗(包括支持和姑息治疗)以及研究的建议。